Illumina releases SpliceAI2 for genetic variant research

Oct 8, 2026
SpliceAI2 predicts how genetic variants affect RNA splicing and identified 17% more disease relevant variants than competing models in a rare disease dataset.

Illumina introduced SpliceAI2 in a press release, describing the model as a tool for predicting how genetic variants affect RNA splicing. In a rare disease research dataset, the model identified 17% more disease relevant splice variants than alternative models.

SpliceAI2 was trained on a dataset 100 times larger than the dataset used for the original SpliceAI. Illumina said an analysis of matched whole genome and RNA sequencing data found that it improved measurements of splice site usage by 34% compared with the next best model.

The model joins PromoterAI and PrimateAI-3D in Illumina's genomic AI tools for assessing splice, promoter and missense variants. Researchers can access SpliceAI2 through the company's DRAGEN Annotation and Emedgene applications.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.